Claim 1: A peptide-oligomer conjugate of formula (1) or a pharmaceutically acceptable salt thereof, wherein R³ is selected from OH, -N (H) CH₂C (O) NH₂,-N (c832131-8326262 tar) ch8322； C (o) n8322；1. A formula compound (2) and a formula compound (3)；R⁵ is -C (O) (O-alkyl) ˣOH, where x is 3-10 and each alkyl group is, independently in each case, C₂₋₆-alkyl, or R⁵ is selected from the group consisting of -C ( O) C₁₋₆-alkyl, trityl, monomethoxytrityl, - (C₁₋₆-alkyl) R⁶,-(c83218331-832626-heterogeneous) - r8310a；aril-R⁶,Infidel r8310a,-C (O) O- (C -alquil) -R-C (O) O-aril-R-C (o) o-heteromorphic-r8310 and R1；R8310 is selected from Oh, SH and n832222；O r8310es o, s or NH, proportional to a solid support； R1 is a separate oh-nr8311； R12 o-nr8311； r831222；each R⁷ and R⁸ is, independently in each case, H or -C₁₋₆-alkyl； R² is selected, independently in each case, from the group consisting of H, a nucleobase and a nucleobase functionalized with a protective chemical group, where the nucleobase, independently in each case, comprises a C₃₋₆ heterocyclic ring selected from pyridine, pyrimidine, triazinan, purine and deaza-purine； z is 8-40； R⁴ is selected from H, -C₁₋₆-alkyl, -C (O) C₁₋₆-alkyl, benzyl, stearyl, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl, a compound of formula (4) and R²；R es -C (O) (CH) C (O) - o -C (O) (CH) S (CH) C (O) -R es - (CH) OC (O) N ((CH) N (H) C (3DNH) NH)R1 was selected from Oh y-nr8311； r831222；R2. Select from the group consisting of formula group (5)；N is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10； P is 2, 3, 4 or 5； R 1 cube is a link or is selected from the formula group (6)；R¹⁵ and R¹⁹ are selected, independently in each case, from the group consisting of H, -C₁₋₄-alkyl, -CH (-C₁₋₄-alkyl) ₂ and - (CH₂) ₃NH-C (= NH) -NH₂ ；T and W are 2, 3, 4 or 5, respectively； r830808 is selected from the formula group (7)；R¹⁷ is H or -C₁₋₄-alkyl； R²⁰ is selected from the group consisting of H, -C₁₋₄-alkyl, -CH (-C₁₋₄-alkyl) ₂ and - (CH₂) ₃NH-C (= NH) -N
